Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Total Liabilities: 2021-2025

Historic Total Liabilities for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $1.8 million.

  • InMed Pharmaceuticals' Total Liabilities fell 14.46% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 14.46%. This contributed to the annual value of $2.1 million for FY2025, which is 18.00% down from last year.
  • InMed Pharmaceuticals' Total Liabilities amounted to $1.8 million in Q3 2025, which was down 17.48% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Total Liabilities ranged from a high of $5.2 million in Q4 2021 and a low of $1.3 million during Q3 2023.
  • Moreover, its 3-year median value for Total Liabilities was $2.3 million (2024), whereas its average is $2.1 million.
  • In the last 5 years, InMed Pharmaceuticals' Total Liabilities skyrocketed by 69.85% in 2022 and then crashed by 62.55% in 2023.
  • Over the past 5 years, InMed Pharmaceuticals' Total Liabilities (Quarterly) stood at $5.2 million in 2021, then plummeted by 50.45% to $2.6 million in 2022, then decreased by 3.92% to $2.5 million in 2023, then dropped by 6.57% to $2.3 million in 2024, then dropped by 14.46% to $1.8 million in 2025.
  • Its Total Liabilities was $1.8 million in Q3 2025, compared to $2.1 million in Q2 2025 and $2.3 million in Q1 2025.